Inactivation of bovine plasma amine oxidase by 1,1,1-trihalo-3-aminopropanes

被引:3
|
作者
Kim, Jisook [1 ]
Lee, Irene N. [2 ]
机构
[1] Univ Tennessee, Dept Chem & Phys, Chattanooga, TN 37403 USA
[2] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA
基金
美国国家卫生研究院;
关键词
Amine oxidase; Copper amine oxidase; Quinone; Trihaloaminopropane; TOPA QUINONE; ACTIVE-SITE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; SSAO ACTIVITY; IDENTIFICATION; TOPAQUINONE; SUBSTRATE; COFACTOR; KETONES;
D O I
10.1016/j.bioorg.2017.10.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this paper, we report the inactivation of copper containing bovine plasma amine oxidase (BPAO) by a series of saturated alkylamines containing halogen atoms at gamma-position, which are 1,1,1-trihalo-3-aminopropane, 1,1,1-trifluoro-2-hydroxy-3-aminopropane, 1,1,1-trichloro-2-hydroxy-3-aminopropane, and 1,1,1-trichloro-2-(2-phenethyloxy)-3-aminopropane. The trihalo-2-hydroxypropylamine analogs exhibited a time-dependent inactivation behavior of BPAO, with 1,1,1-trifluoro-2-hydroxy-3-aminopro pane as the most efficient inactivator. The incorporation of a OH group at beta-position increased inactivation efficiency by 10-fold within the trifluoro analogs, and the incorporation of a phenethyloxy group at beta-position exhibited a higher efficiency by 3-fold within the trichloro analogs based on I-75 values. All four compounds were found to be irreversible inactivators for BPAO. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:265 / 273
页数:9
相关论文
共 50 条
  • [1] Inactivation of bovine plasma amine oxidase by haloallylamines
    Kim, J
    Zhang, YM
    Ran, CZ
    Sayre, LM
    BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (05) : 1444 - 1453
  • [2] Reversible inactivation of bovine plasma amine oxidase by cysteamine and related analogs
    Jeon, Heung Bae
    Jang, Yujin
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 403 (3-4) : 442 - 446
  • [3] Inactivation of bovine plasma amine oxidase by 4-aryloxy-2-butynamines and related analogs
    Jeon, HB
    Sun, G
    Sayre, LM
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2003, 1647 (1-2): : 343 - 354
  • [4] Discovery of a Sensitive, Selective, and Tightly Binding Fluorogenic Substrate of Bovine Plasma Amine Oxidase
    Ling, Ke-Qing
    Sayre, Lawrence M.
    JOURNAL OF ORGANIC CHEMISTRY, 2009, 74 (01) : 339 - 350
  • [5] Highly potent propargylamine and allylamine inhibitors of bovine plasma amine oxidase
    Jeon, HB
    Sayre, LM
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 304 (04) : 788 - 794
  • [6] HPLC-UV assay for the evaluation of inhibitors of plasma amine oxidase using crude bovine plasma
    Mergemeier, Kira
    Galster, Florian
    Lehr, Matthias
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2019, 34 (01) : 144 - 149
  • [7] The precursor form of Hansenula polymorpha copper amine oxidase 1 in complex with CuI and CoII
    Klema, Valerie J.
    Johnson, Bryan J.
    Klinman, Judith P.
    Wilmot, Carrie M.
    ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS, 2012, 68 : 501 - 510
  • [8] Highly potent 3-pyrroline mechanism-based inhibitors of bovine plasma amine oxidase and mass spectrometric confirmation of cofactor derivatization
    Zhang, Yuming
    Ran, Chongzhao
    Zhou, Guangyin
    Sayre, Lawrence M.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (04) : 1868 - 1877
  • [9] The discovery and development of selective 3-fluoro-4-aryloxyallylamine inhibitors of the amine oxidase activity of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1)
    Foot, Jonathan S.
    Deodhar, Mandar
    Turner, Craig I.
    Yin, Ping
    van Dam, Ellen M.
    Silva, Diego G.
    Olivieri, Aldo
    Holt, Andrew
    McDonald, Ian A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (12) : 3935 - 3940
  • [10] Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: a patent survey
    Dunkel, Petra
    Balogh, Balazs
    Meleddu, Rita
    Maccioni, Elias
    Gyires, Klara
    Matyus, Peter
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (09) : 1453 - 1471